Last reviewed · How we verify
NCT06681636: HPV9vxFSW
Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure
Phase 2 trial testing Human papillomavirus 9-valent vaccine, Recombinant in HPV Infection in 300 participants. Not yet recruiting.
31 October 2026
Quick facts
| Lead sponsor | National Institute of Hygiene and Epidemiology, Vietnam |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 300 |
| Start date | 14 December 2024 |
| Primary completion | 31 October 2026 |
| Estimated completion | 31 December 2027 |
| Sites | 3 locations across Vietnam, Australia |
Drugs / interventions tested
- Human papillomavirus 9-valent vaccine, Recombinant — full drug profile →
Conditions studied
- HPV Infection — all drugs for HPV Infection →
- Cervical Cancer — all drugs for Cervical Cancer →
- Anogenital Cancer — all drugs for Anogenital Cancer →
- Anogenital Warts — all drugs for Anogenital Warts →
Sponsor
National Institute of Hygiene and Epidemiology, Vietnam
Who can join
Adults 18 to 26, female only, with HPV Infection or Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Study to evaluate if the 3 dose extended schedule (0-6-18 months) for the HPV vaccine Gardasil-9 provide similar immune responses and short term protection against HPV infection compared to the regular 3 dose schedule (0-2-6 months) in high risk women in Vietnam
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06681636
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HPV Infection
Currently open trials in the same condition.
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07281677 — Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years · Phase 4 · recruiting
- NCT06507917 — Concordance and Acceptability of Self-screening Versus Screening by a Healthcare Professional for HPV, a Risk Factor for · NA · recruiting
- NCT07336134 — PopSci CHW4CervixHealth · NA · recruiting
- NCT06959563 — Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV · EARLY_PHASE1 · active not recruiting
Other National Institute of Hygiene and Epidemiology, Vietnam trials
Trials by the same sponsor.
- NCT03282370 — Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam · Phase 3 · completed
- NCT03204227 — Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06681636 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Hygiene and Epidemiology, Vietnam
- Last refreshed: 8 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06681636.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing